• contact us navContact Us
  • search navSearch
Let's connect

Want to discuss your project or have any questions?

Drug–drug interactions

Object or precipitant? Expert in vitro DDI studies

Evaluating potential drug–drug interactions (DDIs) between co-administered drugs is essential for the registration of new drugs.
Liquid handling machine from the inside filling a plate

Expert in vitro DDI studies

Evaluating DDIs between co-administered drugs is essential for new drug registration. In vitro DDI studies, particularly those involving cytochrome P450 (CYP) enzymes, are recommended for first-in-human (FiH) trials to help guide participant selection and concomitant medications. 
Our assays assess a drug candidate's potential to act as a DDI object or precipitant, complying with international regulatory requirements, including ICH M12 guidelines. Our DDI portfolio includes drug-metabolising enzyme (DME) phenotyping, inhibition, induction, and drug transporter phenotyping and inhibition, supporting your drug development process.

 
v.1.1.1203